Anelia V. Delcheva

Anelia V. Delcheva

Morrison & Foerster LLP

Contact  |  View Bio  |  RSS

Latest Posts › Pharmaceutical

Share:

MoFo BioMeter - Vol. 2, Issue 4, November 2013 - Q3 BioMeter Shows Strong Early Stage Deals

The average BioMeter value in the third quarter of 2013 was $30.4 million, an increase from the $22.2 million value in the second quarter. Like last quarter, Phase 1 and Phase 2 transactions showed very strong results, with...more

11/26/2013 - Biotechnology Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 2, Issue 3, August 2013 - Q2 BioMeter Encouraging for Products from Early Development through Phase 2

The average BioMeter value in the second quarter of 2013 was $22.2 million, an increase from the $16.3 million value in the first quarter (excluding BMS/Rickets and AZ/Moderna), and down from $59.4 million in the first...more

8/29/2013 - Biotechnology Pharmaceutical

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/31/2013 - Biotechnology OTC Pharmaceutical Prescription Drugs Valuation

3 Results
|
View per page
Page: of 1

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.
×